A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLL

NCT04876092 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma, Non-Hodgkin

Interventions

DRUG: JNJ-67856633
DRUG: Ibrutinib

Sponsor

Janssen Research & Development, LLC